220
Participants
Start Date
September 30, 2019
Primary Completion Date
October 30, 2025
Study Completion Date
September 30, 2026
Botulinum Toxin Type A Injection [Xeomin]
Before the main stage of the surgery, botulinum toxin will be injected into the entire visible area of the 4 major epicardial fat pads, during extra corporal circulation and before aortic cross clamping in order to reduce the time of ischemia.
Drug placebo
All patients from the control group will receive placebo. Before the main stage of the surgery, during extra corporal circulation and before aortic cross clamping, the placebo will be injected into the entire visible area of the 4 major epicardial fat pads as follows (1 mL at each fat pad).
ACTIVE_NOT_RECRUITING
Hôpital Saint-Joseph, Marseille
RECRUITING
Institut Mutualiste Montsouris, Paris
RECRUITING
Hôpital Européen Georges Pompidou, Paris
WITHDRAWN
Hôpital Bichat, Paris
ACTIVE_NOT_RECRUITING
Clinique Ambroise Paré, Neuilly-sur-Seine
WITHDRAWN
Centre Cardiologique du Nord, Saint-Denis
ACTIVE_NOT_RECRUITING
Corentin Celton, Issy-les-Moulineaux
ACTIVE_NOT_RECRUITING
Hôpital Marie Lannelongue, Le Plessis-Robinson
ACTIVE_NOT_RECRUITING
CHU Limoges, Limoges
Collaborators (1)
Merz Pharmaceuticals
INDUSTRY
Ministry of Health, France
OTHER_GOV
Assistance Publique - Hôpitaux de Paris
OTHER